MedTrace Logo

Liposomal Bupivacaine Versus Standard of Care in Total Knee Surgery

NCT02219087 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-01-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether liposomal bupivacaine is effective in the management of pain following total knee arthroplasty, as compared to standard of care analgesia.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

Liposomal bupivacaine

DRUG

Standard of Care

Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.

Sponsors & Collaborators

  • OhioHealth

    lead OTHER

Principal Investigators

  • Robert Fada, MD · OhioHealth

  • Sara Jordan, PharmD, BCPS · OhioHealth

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02219087 on ClinicalTrials.gov